Myovant Sciences Ltd. (NYSE:MYOV) will hold its 2Q21 earnings conference call with the financial community on 12th November 2020 at 8:30 AM Eastern Time.
The conference call will be webcast live on Internet at myovant.com
Alternatively, callers may dial the number(s) 1-800-532-3746 Toll Free or +1-470-495-9166 Toll Number
Earnings Expectation
Myovant Sciences Ltd. is expected to report second quarter earnings results, before market open, on Thursday 12th November 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.73 per share from revenue of $ 0.29 million. Looking ahead, the full year loss are expected at $ 2.66 per share on the revenues of $ 38.80 million.
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womens health and endocrine diseases. The companys lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction.
